Breast Cancer Treatment Consensus St. Gallen 2007: Unity in Diversity?

Adjuvant therapy of primary breast cancer: Consensus Conference, St. Gallen

he International Consensus Conference in St. Gallen, Switzerland, on adjuvant therapy of primary breast cancer was one of the most important scientific meetings in the field, besides the NIH Consensus Development Conference (1). It brought together about 3,000 people. The abstracts were published in the Supplement 1 of the journal The Breast. The Consensus Statements are expected to be publishe...

Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.

Endocrine treatment for breast cancer was introduced more than a century ago. The discovery of hormone receptors has allowed targeting of endocrine treatment to patients whose primary tumours express these receptors. In the adjuvant setting, different approaches are used in premenopausal or postmenopausal women. In premenopausal patients, suppression of ovarian function and the use of tamoxifen...

International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland.

Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer.

This final paper of the proceedings of the recent Eighth St. Gallen Conference 2003 on the Primary Therapy of Early Breast Cancer comments on the Consensus Paper put forth by the international expert panel and emphasizes new information, that has emerged during the 2 years since the seventh such meeting in 2001. More than 3200 breast cancer specialists from various medical fields-coming from 75...

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, sys...